Subsequently, osimertinib, a third-generation EGFR TKI that inhibits both EGFR TKI sensitizing and T790M resistant mutations, was studied in metastatic EGFR-mutated NSCLC and showed significant OS benefit compared to erlotinib or gefitinib with a median OS of 38.6 months (95% CI: 34.5–41.8) in the osimertinib arm [62]. Here, EGFR is linked to non-small cell lung carcinoma.